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Abstract
Background: Fibrous dysplasia (FD) is a benign bone tumor which most commonly involves the craniofacial skeleton. The
most devastating consequence of craniofacial FD (CFD) is loss of vision due to optic nerve compression (ONC). Radiological
evidence of ONC is common, however the management of this condition is not well established. Our objective was to
compare the long-term outcome of patients with optic nerve compression (ONC) due to craniofacial fibrous dysplasia (CFD)
who either underwent surgery or were managed expectantly.
Methodology/Principal Findings: We performed a meta-analysis of 27 studies along with analysis of the records of a cohort
of patients enrolled in National Institutes of Health (NIH) protocol 98-D-0145, entitled Screening and Natural History of
Fibrous Dysplasia, with a diagnosis of CFD. The study group consisted of 241 patients; 122 were enrolled in the NIH study
and 119 were extracted from cases published in the literature. The median follow-up period was 54 months (range, 6–228
months). A total of 368 optic nerves were investigated. All clinically impaired optic nerves (n=86, 23.3%) underwent
therapeutic decompression. Of the 282 clinically intact nerves, 41 (15%) were surgically decompressed and 241 (85%) were
followed expectantly. Improvement in visual function was reported in fifty-eight (67.4%) of the clinically impaired nerves
after surgery. In the intact nerves group, long-term stable vision was achieved in 31/45 (75.6%) of the operated nerves,
compared to 229/241 (95.1%) of the non-operated ones (p=0.0003). Surgery in asymptomatic patients was associated with
visual deterioration (RR 4.89; 95% CI 2.26–10.59).
Conclusions: Most patients with CFD will remain asymptomatic during long-term follow-up. Expectant management is
recommended in asymptomatic patients even in the presence of radiological evidence of ONC.
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Introduction
Fibrous dysplasia (FD) is a benign, slowly growing fibro-osseous
disease accounting for 5–10% of all bone tumors. The skull base is
the most common site of involvement in the craniofacial skeleton
[1]. The pathophysiologic process involves the replacement of
normal bone with immature bone marrow stromal cells whose
differentiation was arrested due to somatic missense mutations in
the gene GNAS on chromosome 20 [2,3]. The disease can involve a
single bone (monostotic variant), multiple bones (polyostotic
variant), or present in combination with hyperfunctioning endocri-
nopathies (e.g. precocious puberty and hyperthyroidism) known as
the McCune Albright syndrome (MAS) [4,5]. The symptoms
associated with FD are well described in the literature, with some
series reporting up to one-third of patients having visual complaints,
including blurred vision, diplopia, and epiphora [6]. The most
devastating consequence of CFD is the loss of vision due to optic
nerve compression (ONC). Although radiological evidence of ONC
in CFD is found in 50–90% of the patients [6], the management of
these patients is more often based on personal experience and/or
expert opinion.
Earlier reports on a cohort of patients from a single center who
presentedformedical treatment byLeeetaland Cutleretalshowed
that most ONC is asymptomatic. However the natural history of
CFDthat includes subjectsreportingforsurgical management is not
well documented [6,7]. Here we report the long-term visual
outcome of patients who had either undergone surgery or were
managed expectantly. Towards this end, we reviewed the clinical
records of FD patients seen at the National Institutes of Health
(NIH) since 1998 together with all published cases found in the
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25179literature. A meta-analysis performed revealed better results in
patients managed expectantly than those undergoing prophylactic
decompression.
Methods
Objective
To compare the long-term outcome of patients with optic nerve
compression (ONC) due to craniofacial fibrous dysplasia (CFD)
who either underwent surgery or were managed expectantly.
Participants
The records of all patients diagnosed as having CFD and who
were enrolled in National Institutes of Health (NIH) protocol 98-D-
0145, entitled Screening and Natural History of Fibrous Dysplasia,
seen between 1998 and 2010 were evaluated. The diagnosis of CFD
was made based on the results of clinical, radiographic, and
histological studies. CFD was identified by computer tomography
(CT) analyses. All patients underwent testing of all relevant
endocrine axes. A diagnosis of growth hormone (GH) excess was
made on the basis of a serum GH level .1.0 ng/ml measured
60 minutes after a standard oral glucose tolerance test. Each study
patient had a neuro-ophthalmologic evaluation by the same neuro-
ophthalmologist (EJF) that included best-corrected visual acuity,
according to the Early Treatment Diabetic Retinopathy Study scale
(20/20 denotes perfect vision), visual fields obtained with the
Humphrey Visual Field Analyzer (Humphrey Instruments, San
Leandro, CA) using the Swedish Interactive Thresholding Algo-
rithm (SITA) 30–2 program or Goldmann perimetry testing, color
vision by 14 Ishihara color plates, contrast sensitivity testing using
the Pelli Robson charts, and funduscopy. Abnormalities suggestive
of optic neuropathy were defined as either an abnormal result on
the visual field test (such as scotoma or field deficit) or an abnormal
result on two of the three other tests performed (specifically, visual
acuity ,20/40, correct identification of ,10 of 14 Ishihara color
plates, or evidence of optic atrophy on funduscopy). All patients
underwent standardized CT imaging of the cranium on either a 4-
or 8-slice helical scanner, with a slice reconstruction interval of
1.25–1.50 mm. The patients’ demographic and clinical data are
summarized in table 1.
Meta analysis search strategy and selection criteria
During October 2010, we conducted a systematic electronic
literature database search of PubMed, CINAHL, Cochrane
Central Register of Clinical Trials, Cochrane Database of
Systematic Reviews and Google from 1975 to 2010. The searches
were conducted using the Medical Subject Heading (MeSH)
terms (fibrous dysplasia) AND (orbit OR vision OR visual OR
optic OR exophthalmos OR diplopia OR proptosis) and limited
to ‘‘Human’’. Reference lists of retrieved manuscripts were hand-
searched for additional publications. Eighteen publications in a
language other than English that could not be translated because
of resource constraints were excluded. Two reviewers (M.A. and
Z.G.) independently screened all titles available as well as
abstracts produced by the electronic search strategies. Articles
were rejected at the initial screening if titles or abstracts showed
that they were clearly irrelevant. The full text of potentially
relevant articles was reviewed to assess their suitability for
inclusion in this meta-analysis. Study selection process is
described in figure 1. Inclusion criteria according to the study
design were any randomized controlled trial, prospective and
retrospective cohorts, case-control study designs, case reports and
case series. Criteria for study population inclusion were
histopathologic diagnosis of CFD, radiologically confirmed optic
canal narrowing, pre- and post-treatment visual status (based on
visual fields and visual acuity), and .4m o n t h so ff o l l o w - u p .T h e
included studies are listed in Tables S1, S2, S3 (supplemen-
tary material) [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,
24,25,26,27,28,29,30,31,32,33]. Follow-up included periodic (6–
12 months) radiological imaging with CT and MRI as well as
ophthalmologic exams.
Assessment of study quality and risk of bias
Two independent reviewers assessed both the quality and risk of
bias of the included publications. They were not blinded to
publication details, but measures were taken to obscure outcome
assessment, avoid the description of incomplete outcome data, and
assess the risk of selective outcome reporting. All the included
studies were rated by the Oxford Centre for Evidence-based
Medicine suggested levels of evidence according to the study
designs.
Table 1. Demographic and clinical data of patients seen at the National Institutes of Health (NIH).
Total
{
(n=122)
Asymptomatic
patients without
surgery
(n=108)
Asymptomatic
patients undergoing
surgery
(n=8)
Symptomatic
patients undergoing
surgery
(n=11)
p Value of
asymptomatic,
observation vs
surgery
pV a l u eo f ,
symptomatic vs
asymptomatic
Age (years)
* 20617 21618 20613 1465 0.15 1.41
Male/female 50/72 45/63 4/4 4/7 0.71 0.6577
Polyostotic/MAS 18/104 16/92 2/6 2/9 0.6 0.16
Craniofacial pain 50 (41%) 46 (43%) 6 (75%) 6 (55%) 0.13 0.63
Cosmetic deformity 84 (69%) 72 (67%) 7 (88%) 10 (91%) 0.43 1
Cafe ´ o lait 85 (70%) 73 (68%) 6 (75%) 9 (82%) 1 1
Precocious puberty 61 (50%) 53 (49%) 3 (38%) 7 (64%) 0.71 0.36
Thyroid abnormalities 83 (68%) 73 (68%) 6 (75%) 9 (82%) 1 1
Growth hormone excess 28 (23%) 22 (20%) 4 (50%) 5 (45%) 0.07 1
Follow-up years 8.463.37 8.463.3 9.663.5 7.464.3 0.98 1.18
*Age at date of NIH enrollment, mean 6 standard deviation.
{Five patients had different management for each eye and were counted twice.
MAS=McCune Albright syndrome.
doi:10.1371/journal.pone.0025179.t001
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The two reviewers independently checked each case, and all
available specific data and endpoints were recorded for each patient.
In addition, the authors of the included articles were contacted by
email (when available) for additional information on patient follow-
up. Discrepancies between the two reviewers were resolved by
discussion and consensus. They were not blinded to publication
details, but used identical abstraction forms to record the collected
data. Details on the individual patient’s gender were not always
available. Symptomatic or clinical impairments were defined by the
presence of a visual field defect or reduced corrected visual acuity.
Ethics
The study was conducted according to an institutional review
board-approved protocol (National Institutes of Health protocol
98-D-0145) and the participants or their guardians gave a written
informed consent.
Statistical methods
Risk ratios and 95% confidence intervals (CIs) were calculated
for the individual endpoints. Clinical heterogeneity was assessed by
comparison of effect sizes between symptomatic patients who
underwent ON decompression, asymptomatic patients who
underwent optic nerve decompression, and asymptomatic patients
who were managed expectantly. Differences between these three
groups were tested using a standard Fisher Exact test (on two
degrees of freedom). A two-sided p value,0N05 was considered
statistically significant. An independent T test was performed to
compare the means of continuous variables using a 95% CI for the
difference. Statistical analyses were performed using the SAS
software package (SAS Institute, Cary, North Carolina by a
certified statistician). The meta-analysis was performed in
compliance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [34].
Results
The study selection process is displayed in Fig. 1. Fifty relevant
articles were reviewed, of which 20 were excluded due to
insufficient data or for inability to meet the inclusion criteria
(e.g., lack of essential data, follow-up ,4 months). Two
publications describing the same study population were excluded
[7], and a third one was excluded due to the administration of
high-dose biphosphonate treatment [35]. We excluded one
symptomatic patient in our cohort with extensive disease that
was inoperable. Two patients were considered to be asymptomatic
because the visual disturbances described were stable, subtle and
did not meet the definition of optic neuropathy.
The final study group consisted of 241 patients: 122 were
enrolled in the NIH study and 119 were extracted from published
cases in the literature. The FD was classified as being monostotic
in 72 (30%) cases and as polyostotic in 50 (21%) cases. MAS was
diagnosed in 119 (49%) patients. The median age at CFD
Figure 1. Flow chart of the study selection process.
doi:10.1371/journal.pone.0025179.g001
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up period was 54 months (range, 6–228 months).
A total of 368 optic nerves were studied, 127 (35%) of them
involved both eyes. All patients with clinically impaired optic
nerves (i.e. an objective evidence of visual disturbance) (n=86
nerves, 23.3%) underwent therapeutic optic nerve decompression.
Of the 282 asymptomatic ONC, 41 (15%) were decompressed
prophylactically and 241 (85%) were followed expectantly. There
was no significant difference in the mean age of the patients in the
three study groups: 22611 years (range 8–55) for the symptomatic
patients, 1967 years (range 11–37) for the asymptomatic operated
group, and 2168 years (range12–26) for the asymptomatic non-
operated group (p=0N36). There was also no difference in the
follow-up period for the operated and non-operated cohorts of
asymptomatic patients (96644 and 102616, respectively;
p=0N57), while the follow-up period for the symptomatic patients
cohort was significantly shorter (42627 months; p,0N001). The
distribution of FD among the symptomatic and asymptomatic
operated patients was similar (monostotic, polyostotic, and MAS
rates of 39, 19, and 17 and 22, 9, and 7%, respectively). There was
a significantly higher rate of MAS in the non-operated patients
group (n=95, 73% p,0N0001).
The visual outcome in the three groups revealed that 58 (67.4%)
of the clinically impaired nerves that underwent surgical
decompression had better postoperative visual function than
before surgery. Among those subjects who had normal vision
but underwent prophylactic optic nerve decompression, long-term
stable vision was achieved in 31 (75.6%) of the operated nerves,
compared to 229 (95.1%) of the non-operated nerves (three way
ANCOVA, p=0N0003). Surgery in asymptomatic patients was
associated with worse postoperative visual function, and a relative
risk of 4.89 (95% CIs of 2.26–10.59) for impaired optic nerve
function. The type of CFD (MAS, monostotic or polyostotic
variants) or GH access were not associated with postoperative
worsening of visual outcome in any of the groups (p.0N05), as
shown in table 2.
In order to confirm our results, we repeated the analysis on the
122 patients who were followed in a single institution (NIH). In
agreement with our previous findings, there were no significant
demographic or clinical differences between the three groups
(table 1). Statistical analyses of this single institution cohort
showed that better visual outcome was achieved in 9 out of 14
(64%) clinically impaired operated nerves after surgery in
symptomatic patients. Similar to the findings from the pooled
data, long-term stable vision of the non-clinically impaired nerves
was achieved in 60% of the operated nerves, and in 97.2% non-
operated nerves.
Discussion
Radiological evidence of optic canal involvement in CFD is
relatively common [7]. ONC can result from primary CFD of the
sphenoid bone or from secondary lesions, including cystic FD,
mucoceles, hemorrhage, and aneurysmal bone cysts [27]. While
there is consensus that therapeutic decompression of the optic
nerve is indicated for symptomatic patients, the question of
whether to operate on asymptomatic patients is an ongoing
controversial issue [6,8,13,36]. Earlier studies had reported visual
impairment in 20–80% of patients with ONC [19,23]. Similarly,
Chen et al reported that one-third of CFD patients will have visual
deficits, and two-thirds will report some degree of visual
disturbance if optic canal involvement is demonstrated by imaging
[8]. Due to the potential risk of rapidly progressing visual
deterioration and irreversible optic nerve atrophy, many studies
suggest prophylactic decompression of the nerve in asymptomatic
CFD patients with radiologic evidence of optic nerve compression
[8,37,38]. Contrary to these studies, Lee et al reported in her
sentinel study that the vast majority of asymptomatic patients with
CFD will demonstrate normal vision despite radiological evidence
of optic nerve compression, but this cohort did not include a group
managed with optic nerve decompression [6]. In a subsequent
study on patients from the same institution that included
additional subjects (n=87), Cutler et al, reported no age-related
progression to optic neuropathy in these patients.
In the current study, we analyzed the long term follow up data
of the patients from the NIH that now also included information
regarding treatment and long term follow up (n=122). In
addition, we performed a meta-analysis of all reported cases of
patients with radiologic evidence of optic nerve compression. A
total of 368 nerves were included in our study, and long-term
follow-up of their visual outcome revealed that surgery in
asymptomatic patients is associated with worse prognosis com-
pared to the outcome of asymptomatic patients who are managed
expectantly. These results are further supported by the similar
results that emerged from our analysis of the data from a single
institution.
The majority of the patients in our cohort had MAS. In the
current analysis, there was not a significant difference in the
prevalence of GH excess between expectantly managed patients
and asymptomatic patients who underwent surgery (table 1),
eliminating GH excess as a potential confounder. In an earlier
analysis of a subgroup of this population, we had demonstrated an
association between increased GH secretion and optic neuropathy
[7]. However, in the current analysis of the larger population,
there was no longer a statistically significant association between
GH excess and vision loss (p=0.07). We think this represents a
change in the patient population due to a change in patient
recruitment. Since our earlier publications suggested and found a
GH effect on optic neuropathy, we have subsequently been
actively recruited young subjects with GH excess and initiated
treatment for GH excess as early as possible in an effort to see if
long term GH excess morbidity could be averted with treatment.
Our most recent analysis of the data on the effect of early detection
Table 2. Visual deterioration by disease type
*.
Therapeutic surgery Prophylactic surgery Watchful waiting
Monostotic FD 19/41 (46%) 4/23 (17%) 2/17 (11%)
Polyostotic FD 4/21 (19%) 2/11 (18%) 3/39 (8%)
MAS 10/24 (41%) 2/7 (28%) 6/186 (3%)
*No correlation reached a level of significance.
FD=fibrous dysplasia, MAS=McCune Albright’s syndrome.
doi:10.1371/journal.pone.0025179.t002
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able to show that vision loss in association with GH excess was
only seen in subjects whose diagnosis and treatment was delayed
until adulthood and that none of the subjects who were diagnosed
and treated in childhood had visual disturbances [39].
Optic nerve decompression in the asymptomatic patients is not
risk free, as cases of blindness and visual deterioration have been
reported [9]. Lei et al attributed a high risk of optic nerve injury to
the sensitivity of the already damaged nerve to surgical insult [40].
Three patients in our cohort who underwent simultaneous or
sequential prophylactic decompression in the contralateral eye
resulted in bilateral blindness. Partial decompression of the optic
canal was also suggested as a means for reducing the pressure on
the nerve in symptomatic patients. One retrospective review of
different surgical techniques and equipment failed to demonstrate
any advantage of one particular technology [13]. Thus, risk of
nerve injury in asymptomatic patients raises some questions about
the actual utility of nerve decompression, especially since disease
progression cannot be determined. Furthermore, it is not possible
to predict which patient will benefit from the procedure.
Limitations
There are several limitations related to the design of our current
study. First, due to referral bias, there are a higher proportion of
patients with MAS in the expectantly managed group than in the
FD patient population. Given that MAS is considered a more
aggressive variant of the disease, it is conceivable that our
population will have a higher risk for ONC. Nevertheless, we did
not observe any advantage for carrying out decompression in
asymptomatic patients regardless of their GH levels. Second, the
retrospective nature of this work precluded our ability to control
confounding variables. For example, we did not analyze other
features which differed between the operated patients, such as the
type of surgery.
Conclusions
While patients with CFD and radiographic ONC are at
potential risk for visual deterioration, most of them are
asymptomatic and will remain that way. Surgical decompression
should be reserved for symptomatic patients, the majority of whom
will show improvement and good long-term results after optic
nerve decompression. Expectant management, repeated ophthal-
mologic exams, and long-term radiologic follow-up are indicated
in asymptomatic FD patients who have optic nerve encasement.
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